Pharma's Patience Pays Off: Patient Advocates Are Powerful Allies in Part D
This article was originally published in RPM Report
The pharmaceutical industry has long counted on patient advocates as allies in the FDA drug approval process. But their relationship on issues related to drug coverage has often been tense. The Medicare drug benefit has opened a new chapter in the relationship. Patient advocates have worked closely with the Centers for Medicare & Medicaid Services in the early months of Part D, and they have had an impact. Industry's long-time effort to establish alliances is paying off.
You may also be interested in...
Prestwick's Huntington's chorea therapy won FDA approval in August, triggering a flurry of deals valued at over $1 billion. Not bad for a 50-year-old drug expected to treat no more than 5,000 patients-and a powerful case study in how embracing the new regulatory realities can pay off.
Despite its ultra-orphan indication, Xenazine is likely to provide a very attractive return on its development costs. It's a model that could work for other drugs-but only when several key factors work together.
The Democratic leadership rammed a major health bill through the House this summer, including some Medicare Part D fixes that read like a Big Pharma wish list. Have the industry's toughest critics gone soft?